The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Midatech Pharma (MTPH) also announced on the 20th of April 2020 that they were considering a sale of the company as part of their strategic review:
https://www.lse.co.uk/rns/MTPH/strategic-review-update-formal-sale-process-yti6q3s1246frck.html
Midatech Pharma (MTPH) were granted orphan drug designation by the FDA for MTX110. Open Orphan are a leading European rare/orphan focused pharma services company, so acquiring MTPH could be a possibility.
According to the May 2020 corporate overview presentation, the company's cash burn is approximately £0.4 million per month.
http://www.midatechpharma.com/uploads/investor_files/20.05.15%20Midatech%20Overview.pdf
Mologic are involved with a clinical trial for cancer patients that will assess the feasibility of lateral flow assay testing for the detection of IgM and IgG specific antibodies to SARS-CoV-2:
https://clinicaltrials.gov/ct2/show/NCT04427280?cntry=GB&draw=2&rank=4
Phase I Study of Marizomib + Panobinostat:
https://clinicaltrials.gov/ct2/show/NCT04341311
Could Open Orphan acquire MTPH (Midatech Pharma) in order to get IMUTEX listed on Nasdaq?
ORPH owns hVIVO and hVIVO own 49% of IMUTEX.
MTPH is listed on AIM and Nasdaq.
MTPH share price could make it an attractive target, considering its strong cash position.
Thoughts anyone?
Could ORPH (Open Orphan) acquire Midatech Pharma in order to get IMUTEX listed on Nasdaq?
ORPH owns hVIVO and hVIVO own 49% of IMUTEX.
MTPH is listed on AIM and Nasdaq.
MTPH share price could make it an attractive target, considering its strong cash position.
Thoughts anyone?
We're still waiting for the UK Rapid Test Consortium (UK-RTC) lateral flow antibody test details to be announced. Today's RNS just contains details about additional revenue streams and product diversification which is good. We all know where the SP will be heading once the design freeze gets announced by the UK-RTC!
https://www.gov.uk/government/news/trial-of-rapid-coronavirus-test-launched-in-hampshire
Yes, I've received mine.
The website provides a comparison of the commercially available COVID-19 diagnostic tests.
https://www.360dx.com/coronavirus-test-tracker-launched-covid-19-tests
From the Medicines and Healthcare products Regulatory Agency (MHRA):
'We are asking all providers of laboratory-based COVID-19 antibody testing services using capillary blood collected by a fingerprick to temporarily stop providing this service until home collection of this sample type has been properly validated for use with these laboratory tests.'
If the above statements can be verified, this is very good news for Open Orphan.
I've received two PrimaryBid share subscription emails and it seems that the full amount of shares that I requested have been allocated (albeit in two separate amounts).
Hvivo, in regards to the erroneous shares figure that you mentioned, it was noted in the first RNS:
The Company has conditionally raised approximately £80,000 (before expenses) through the Subscription of 727,272 Subscription Shares.
Maybe the 727,272 shares were purchased by Open Orphan employees?
Maybe we're going to purchase a second MosaiQ COVID-19 Antibody Microarray following the fundraising?
* The Group's pipeline of potential new contracts is now in excess of £160 million and includes c.£110 million of near-term contracts within hVIVO and Venn Life Sciences along with new opportunities arising post Covid-19.
* The Directors believe that the increased investment in testing capability will result in companies, such as Open Orphan, benefiting as a provider of testing services.
Excellent news!